Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-01-18
2011-01-18
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S141100, C424S142100, C424S143100, C530S387100, C530S387300, C530S388100, C530S388150, C530S388220
Reexamination Certificate
active
07871611
ABSTRACT:
The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
REFERENCES:
patent: 6084085 (2000-07-01), Baserga
patent: 6300129 (2001-10-01), Lonberg
patent: 6403764 (2002-06-01), Dubaquie
patent: 7020563 (2006-03-01), Bentley
patent: 7037498 (2006-05-01), Cohen
patent: 7147851 (2006-12-01), Ponath et al.
patent: 7217796 (2007-05-01), Wang
patent: 7241444 (2007-07-01), Goetsch et al.
patent: 7378503 (2008-05-01), Graus et al.
patent: 7521053 (2009-04-01), Oliner
patent: 2003/0092631 (2003-05-01), Deshayes
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0235582 (2003-12-01), Singh
patent: 2004/0018191 (2004-01-01), Wang
patent: 2004/0086503 (2004-05-01), Cohen
patent: 2004/0202655 (2004-10-01), Morton
patent: 2004/0228859 (2004-11-01), Graus
patent: 2004/0265307 (2004-12-01), Singh
patent: 2005/0008642 (2005-01-01), Graus
patent: 2005/0059021 (2005-03-01), Farid
patent: 2005/0084906 (2005-04-01), Goetsch
patent: 2005/0136063 (2005-06-01), Wang
patent: 2005/0147612 (2005-07-01), Yayon
patent: 2005/0186203 (2005-08-01), Singh
patent: 2005/0244408 (2005-11-01), Cohen
patent: 2005/0249728 (2005-11-01), Singh
patent: 2005/0249730 (2005-11-01), Goetsch
patent: 2005/0272637 (2005-12-01), Clinton
patent: 2006/0040358 (2006-02-01), Ligensa
patent: 463151 (1996-06-01), None
patent: 1054018 (2000-11-01), None
patent: WO90/00562 (1990-01-01), None
patent: WO93/17105 (1993-09-01), None
patent: WO96/33735 (1996-10-01), None
patent: WO99/28347 (1999-06-01), None
patent: WO99/60023 (1999-11-01), None
patent: WO02/053596 (2002-07-01), None
patent: WO02/072780 (2002-09-01), None
patent: WO02/102973 (2002-12-01), None
patent: WO03/059951 (2003-07-01), None
patent: WO03/100008 (2003-12-01), None
patent: WO03/106621 (2003-12-01), None
patent: WO2004/050850 (2003-12-01), None
patent: WO2004/071529 (2004-08-01), None
patent: WO2004/083248 (2004-09-01), None
patent: WO2004/087756 (2004-10-01), None
patent: WO2005/005635 (2005-01-01), None
patent: WO2005/016967 (2005-02-01), None
patent: WO2005/016970 (2005-02-01), None
patent: WO2005/052005 (2005-06-01), None
patent: WO2005/058967 (2005-06-01), None
patent: WO2005/061541 (2005-07-01), None
patent: WO2005/112969 (2005-12-01), None
patent: WO2006/068953 (2005-12-01), None
patent: WO2006/013472 (2006-02-01), None
patent: WO2006/047639 (2006-05-01), None
patent: WO03/027246 (2009-10-01), None
patent: WO2005/026386 (2009-10-01), None
Brown et al, J Immunol 156(9): 3285-91, May 1996.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Vajdos et al, J Mol Biol 320(2): 415-428, Jul. 5, 2002.
Caldas et al, Mol. Immunol. 39 (15): 941-952, May 2003.
Aburatani et al., “Importance of a CDR H3 basal residue in VH/VL interaction of human antibodies.” J. Biochem., 2002, 132(5):75-782.
Adams et al., “Structure and function of the type 1 insulin-like growth factor receptor” Cell. Mol. Life Sci., 2000, 57:1050-1093.
Arteaga et al., 1989, Cancer Res 49 :6237-6241.
Arteaga et al., 1989, J Clinical Investigation 84:1418-1423.
Bartucci Monica et al. “Differential insulin-like growth factor 1 receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.” 2001, Cancer Res. 61(18):6747-6754.
Brunner et al., “Effect of Endocrine Therapy on Growth of T61 Human Breast Cancer Xenografts is Directly Correlated to Specific Down-regulation of IGF-II” 1993, Euro J Cancer 29A:562-569.
Burtrum et al., 2003, Cancer Research 63:8912-8921.
C. Mitsiades et al. “The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors” 2002, Blood, 100(11):170A.
C. Mitsiades et al. “Gene expression and proteomic profiling of multiple myeloma (MM) cells co-cultured with bone marrow (BM) stromal cells or stimulated with BM-derived cytokines: Implications for therapeutic targeting of the BM milieu in MM.” 2002, Blood, 100(11):811A.
Conover et al., 1987, J Cell Physiol 133:560-566.
Cullen et al., “Insulin-like growth factor receptor expression and function in human breast cancer.” 1990, Cancer Res 50(1): 48-53.
Cullen et al., “Insulin-Like Growth Factor-II Overexpression in MCF-7 Cells Induces Phenotypic Changes Associated with Malignant Progression” 1992, Mol Endocrinol 6:91-100.
Fishwild et al. “High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice.” 1996, Nature Biotechnology 14(7):845-851.
Database EPO Proteins Aug. 6, 2002, EBI accession No. EPOP:AX470348. Database accession No. AX470348.
De Haard et al. 1999, J Biological Chemistry, 274:26 pp. 18218-18230.
De Meyts et al., 2002, Nature Reviews 1:769-783.
Elagib et al. “Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjögren's syndrome.” 1999, Arthritis and Rheumatism, 42(11):2471-2481.
Emery et al. Expert Opinion on Investigational Drugs 3(3):241-251 (Mar. 1994).
Flier et al., 1986, Proc Natl Acad Sci USA 83:664-668.
Furlanetto et al., 1993, Cancer Res 53:2522-2526.
Gansler et al., 1989, American J Pathol 135:961-966.
Garrett et al. “Crystal Structure of the first 3 domains of the type-1 insulin-like growth factor-1 receptor” 1998, Nature, 394(Jul.):395-399.
Gustafson et al., 1990, J Biol Chem 265:18663-18667.
Hailey et al., 2002, Mol Cancer Therapeutics 1 :1349-1353.
Happerfield et al. “The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benigh and malignant breast tissue.” 1997, J. Pathology, 183:412-417.
Harumi et al. “Cloning of porcine IGF1 receptor cDNA and detection of sequence polymorphisms using TR-PCR.” 2001, Animal Genetics, 32(6):387 right column, lines 17-19; and p. 388 left column, line 3 to right col. line 1.
Hekimi et al. “Molecular genetics of life span inC. elegans: how much does it teach us?” 1998, TIG 14(1):14-20.
Hermanto et al., 2000, Cell Growth & Differentiation 11:12, p. 659.
Holzenberger et al. “IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice.” 2003, Nature, 421 (6919):182-187.
Hsin et al. “Signals from reporductive system regulate the life span ofC. elegans.” 1999, Nature 399:pp. 362-366.
Jansson et al., 1997, J Biol Chem 272:8189-8197.
Kalebic et al., 1994, Cancer Res 54:5531-5534.
Karavitaki et al., 2004, Hormones 3:27-36.
Kull et al., 1983, J Biol Chem 258:6561-6566.
Lahm et al., 1994, Intl J Cancer 58 :452-459.
Li et al., 1993, Biochem Biophys Res Comm 196:92-98.
Li et al., 2000, Cancer Immunol Immunotherapy 49:243-252.
Logie et al., 1999, J Mol Endocrinol 23 :23-32.
Lu Dan et al. “Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.” 2004, J. Biol. Chem. 279(4):2856-2865.
Lu Yuhong et al. “Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin)” 2001, J. the Nat Cancer Inst 93(24):1852-1857.
Maloney et al., 2003, Cancer Research 63:5073-5083.
McKern NM et al. “Crystallization of the first 3 domains of the human insulin-like growth factor-1 receptor” 1997, Protein Science N
Calzone Frank J.
Deshpande Rajendra V.
Tsai Mei-Mei
Amgen Inc.
Huynh Phuong
Machin Nathan A.
LandOfFree
Compositions and methods relating to anti IGF-1 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods relating to anti IGF-1 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods relating to anti IGF-1 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2728403